ProMIS Neurosciences Inc. (PMN) stock
Close on Nov 12, 2026Market cap $31.21MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $31.21M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.75
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$38.81M
- EPS, diluted
- -$7.57
- Book value per share
- $4.57
- Diluted shares
- 9M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $3.76
- Open
- $3.76
- Day's range
- $3.40 – $3.84
- Volume
- 128,754
- Average volume (20 days)
- 414,629
- Beta (5 years)
- 0.57
- 52-week range
- $2.78 – $27.40
- RSI (14 days)
- 32.1
- Volatility (1 year)
- 123.4%
- Relative volume
- 0.73×
- WACC
- 7.7%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | PMN | S&P 500 | Difference | PMN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -63.2% | -2.7% | −60.5 pts | ||
| 3 months | -76.0% | -1.7% | −74.3 pts | ||
| Year to date | -49.0% | +11.9% | −60.9 pts | ||
| 1 year | -66.1% | +12.0% | −78.1 pts | ||
| 3 years | -90.3% | +78.2% | −168.4 pts | -54.0% | +21.2% |
| 5 years | -98.3% | +73.2% | −171.5 pts | -55.8% | +11.6% |
| 10 years | -97.4% | +309.6% | −407.1 pts | -30.6% | +15.1% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ProMIS Neurosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Results
- Results
About ProMIS Neurosciences
Pharmaceutical Preparations
ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting neurodegenerative and protein-misfolding disorders. Using its proprietary EpiSelect computational platform, the company predicts conformational disease-specific epitopes to generate humanized monoclonal antibodies and intrabodies that selectively neutralize neurotoxic misfolded proteins without disrupting healthy counterparts. Its pipeline includes PMN310, an antibody candidate undergoing clinical evaluation for Alzheimer’s disease designed to avoid monomer distraction and vascular plaque binding, alongside preclinical programs such as PMN267 for amyotrophic lateral sclerosis and frontotemporal lobar degeneration, and therapeutic candidates directed against alpha-synuclein for synucleinopathies.
Company profile, executives and historyProMIS Neurosciences stock: common questions
What is ProMIS Neurosciences's stock price?
PMN closed at $3.48 on Nov 12, 2026, down 7.45% on the day. Over the past 52 weeks it traded between $2.78 and $27.40.
What is ProMIS Neurosciences's market cap?
ProMIS Neurosciences was worth $31.21M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is PMN's P/E ratio?
ProMIS Neurosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$7.57), so it has no meaningful P/E ratio.
Does ProMIS Neurosciences pay a dividend?
No. ProMIS Neurosciences has not paid a cash dividend over the last twelve months.
When does ProMIS Neurosciences report earnings next?
ProMIS Neurosciences's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has PMN stock performed over the past year?
Including dividends, PMN returned -66.1% over the past year, against +12.0% for the S&P 500.
Who are ProMIS Neurosciences's competitors?
Companies most similar to ProMIS Neurosciences by business, industry and size include ACIU, ANVS, PRTA, VCNX, AMLX.
See a number that looks wrong?